The TEASE-1 trial reveals gildeuretinol's potential to reduce vision loss in Stargardt disease, offering hope for future ...

The ELEVATUM study explored faricimab's effectiveness in treating diabetic macular edema among underrepresented minorities, ...

On the heels of its FDA approval, clinicians weigh in on acoltremon’s (Tryptry) novel mechanism of action and its potential ...

Researchers share that perfluorohexylactane eye drops offer rapid relief for dry eye disease, enhancing patient comfort ...

A study reveals attrition rates in geographic atrophy patients on complement inhibitor therapies, highlighting the need for ...

OCU400 is Ocugen’s novel modifier gene therapy for retinitis pigmentosa (RP). The OCU400 (AAV5-h NR2E3) gene therapy platform ...

VG801 is a dual AAV gene therapy that leverages mRNA trans-splicing via the vgRNA REVeRT and vgAAV platforms to deliver the ...

IVMED-85 is a preservative-free, non-atropine daily drop that slows myopia progression by strengthening scleral and corneal ...

Kiora Pharmaceuticals has granted Senju Pharmaceutical an exclusive option to exercise rights to an exclusive development and ...

Boyer discusses a potential treatment for diabetic retinopathy and macular degeneration using suprachoroidal injections, ...

Prevent Blindness offers resources for Cataract Month, empowering patients and caregivers with knowledge on cataracts and ...

Weighing the benefits and trade-offs of preserved versus preservative-free glaucoma treatments is key to optimizing long-term ...